AAOS: Tissue Regenix Introduces dCELL Platform Technology to the United States

Tissue Regenix, United Kingdom-based developer of regenerative medicine, has established its decellularization (dCELL) Technology in wound care in the United States with plans to expand into other medical sectors. The company has opened up new possibilities in regenerative medicine in the United Kingdom, applying its dCELL Technology to several therapeutic applications. The company launched U.S. operations through their chronic and acute wound care product, DermaPure, and will progress into other applications, including orthopedics in early 2018.
 
The patented dCELL Technology is a multi-tissue regenerative medical platform which can be used in a wide range of medical applications to allow the body to regenerate critical tissue through utilizing decellularized animal and human biological materials. DNA and other cellular material are removed from the tissue, leaving the acellular scaffold intact. dCELL Technology provides support for cell migration during the healing process all while preserving necessary tissue strength. It avoids rejection by the patient’s body and integrates into the host tissue without the use of harsh chemicals or treatments.
 
“We have seen first-hand how life changing these products have been in Europe, and we are thrilled to bring our dCELL Technology to the United States to help a new population of patients heal faster and more effectively,” said Antony Odell, CEO of Tissue Regenix. “These solutions are bringing hope to people who have conditions that may otherwise be beyond repair.”
 
DermaPure, the decellularized human dermis product from Tissue Regenix, is currently available in the United States for patients with hard-to-heal acute and chronic wounds. DermaPure is produced from donated human tissue and it is 99 percent DNA-free. This minimal DNA content closely mimics the structure and function of the native tissue it is replacing. It signals a bio-normal response by not eliminating but reducing inflammation, and stimulates the body to progress through the phases of natural wound healing. Wounds can be healed with as little as one use, potentially providing patients with faster healing and delivering a quicker recovery.
 
Tissue Regenix is currently undertaking clinical trials in the European Union and will look to introduce dCELL Technology to orthopedic applications in the United States in 2018, initially addressing ACL repair.
 
“The application of dCELL Technology in orthopedics will give surgeons and clinicians a new way to provide care to patients requiring anterior cruciate ligament (ACL) reconstruction, meniscus replacement and other injuries,” said Drew Distin, vice president of Orthopedics at Tissue Regenix.
 
Tissue Regenix was founded in the United Kingdom in 2006 to develop and commercialize decellularization research from the University of Leeds and listed on the London Stock Exchange in 2010. Its U.S. headquarters is in San Antonio, Texas. The company’s dCELL Technology removes DNA and other cellular material from animal and human tissue leaving an acellular tissue scaffold which is not rejected by the patient’s body and can be used to repair diseased or worn out body parts. The potential applications of this process are diverse and address many critical clinical needs such as vascular disease, heart valve replacement and knee repair.
 
Tissue Regenix is exhibiting its dCELL Technology this week at the American Academy of Orthopedic Surgeons (AAOS) meeting in San Diego, Calif., (booth 5750).